ClinicalTrials.gg
CompletedNCT03687827SWITCH PROUpdated Jan 12, 2021Results posted

A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study

A Phase 4 interventional study of Insulin degludec and Insulin glargine in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 67 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-12.

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
498
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
18th of 70
498 · median 384
Started
2018
with 4 others
Phase 4
8 of 70
1 open now
Registered
60th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 18th largest by enrollment, is one of 5 that started in 2018, is one of 8 in phase 4, and was the 60th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compares the effect on blood sugar levels of two medicines: insulin degludec and insulin glargine in people with type 2 diabetes. Participants will be treated with insulin degludec and insulin glargine during two different periods. Which treatment participants get first is decided by chance. Both medicines are approved for use in humans and available on the market. They can already be prescribed by participants' doctors. Participants will get pre-filled insulin pens to inject these insulins with. The study will last for about 41 weeks. Participants will visit the clinic 13 times and have 27 phone calls with the study doctor or study staff. At 12 of the clinic visits they will take blood samples. In order to evaluate the changes in participants' blood sugar level over time, participants will be asked to wear a small (35 millimetres (mm) x 5 mm) sensor on the back of participants' upper arm 3 times during the study. Each time participants must wear the sensor for 2 weeks. This sensor is called FreeStyle Libre Pro®. It has a very small tip which is 0.4 mm thick and is inserted 5 mm under participants' skin. Please note that participants will not be able to see the sensor readings while wearing it. The study doctor will show participants the readings when participants return to the clinic. Participants will be asked to fill in a diary in between visits. Participants will have contact with the study doctor or study staff each week. This is to adjust the dose of participants' study medicines and to ensure that participants are well. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age greater than or equal to 18 years at the time of signing
  • Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening
  • Subjects fulfilling at least one of the below criteria:
  • Experienced at least one severe hypoglycaemic episode within the last year prior to screening (according to the American Diabetes Association definition, January 2018)*
  • Moderate renal impairment defined as estimated value of 30-59 mL/min/1.73 m\^2 as defined by Kidney Disease Improving Global Outcomes 2012 at screening
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8 at screening
  • Treated with insulin for more than 5 years
  • Episode of hypoglycaemia (defined a glucose alert value of 70 mg/dL (3.9 mmol/L) or less, i.e., Level 1) within the last 12 weeks prior to screening visit
  • Treated with any basal insulin greater than or equal to 90 days prior to the day of screening with or without any of the following anti-diabetic drugs:
  • Metformin
  • Dipeptidyl peptidase-4 inhibitor
  • Sodium-glucose co-transporter 2 inhibitor
  • Alpha-glucosidase-inhibitors (acarbose)
  • Thiazolidinediones
  • Marketed oral combination products only including the products listed above
  • less than or equal to 9.5% (80 mmol/mol) at screening confirmed by central laboratory analysis
  • less than or equal to 45 kg/m\^2 *Hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery

Exclusion criteria

Exclusion Criteria:

  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, intermittent bolus insulin treatment for periods of no longer than 14 days are permitted prior to the day of screening
  • Anticipated initiation or change in concomitant medications known to affect weight or glucose metabolism (e.g., treatment with orlistat, thyroid hormones, or )
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a pharmacologically pupil-dilated fundus examination performed by an ophthalmologist or another suitably qualified health care provider within the past 90 days prior to screening or in the period between screening and run-in
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
498 participants (actual)

Study arms

  • Experimental
    Insulin degludec

    Participants will receive insulin degludec in period 1 and 2 in a cross-over manner.

    Drug: Insulin degludec

  • Active comparator
    Insulin glargine

    Participants will receive insulin glargine in period 1 and 2 in a cross-over manner.

    Drug: Insulin glargine

Interventions

  • Participants will receive insulin degludec U100 subcutaneous (s.c.) injection once daily for 36 weeks. Doses will be adjusted according to the fasting self-measured plasma glucose (SMPG) values. Participants earlier treated with one or more allowed oral antidiabetic drug(s) (OAD(s)), should continue their pre-trial OAD(s) treatment throughout the trial.

    Also known as: Tresiba®

  • Participants will receive insulin glargine U100 s.c. injection once daily for 36 weeks. Doses will be adjusted according to the fasting SMPG values. Participants earlier treated with one or more allowed OAD(s), should continue their pre-trial OAD(s) treatment throughout the trial.

    Also known as: Lantus®

06

What researchers measure

Primary outcomes

  1. Percentage of Time Spent in Glycaemic Target Range 70-180 mg/dL (3.9-10.0 mmol/L) Both Inclusive, Using Flash Glucose Monitoring (FGM)

    The percentage of time spent in glycaemic target range was calculated as the number of recorded measurements in glycaemic target range (70-180 milligrams per deciliter \[mg/dL\] (3.9-10.0 millimoles per litre \[mmol/L\]), both inclusive) divided by the total number of recorded measurements. The endpoint is based on data recorded by FGM system. It was required that at least 70% of the planned FGM measurements during weeks 16-17 and weeks 34-35 were available for endpoint data to be included in the analysis.

    Time frame: During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2)

Secondary outcomes

  1. Time Spent in Tight Glycaemic Target Range 70-140 mg/dL (3.9-7.8 mmol/L) Both Inclusive, Using Flash Glucose Monitoring

    The percentage of time spent in tight glycaemic target range 70-140 mg/dL (3.9-7.8 mmol/L) both inclusive, during the 2-week maintenance periods using FGM (visit 9-21 (week 16-17) and visit 37-39 (week 34-35)).

    Time frame: During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2).

  2. Time Spent in Nocturnal Glycaemic Target Range 70-140 mg/dL (3.9-7.8 mmol/L) Both Inclusive, in the Nocturnal Period (00:01 am - 05:59 am Both Inclusive) Using Flash Glucose Monitoring

    Percentage of time spent in nocturnal glycaemic target range 70-140 mg/dL (3.9-7.8 mmol/L) both inclusive, in the nocturnal period (00:01 am - 05:59 am both inclusive) during the 2-week maintenance periods using FGM (visit 19-21 (week 16-17) and visit 37-39 (week 34-35)).

    Time frame: During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2).

  3. Level of Glycated Haemoglobin (HbA1c) - Percentage

    Level of HbA1c after two weeks of maintenance periods (Visit 19-21 (week 16-17) and Visit 37-39 (week 34-35)).

    Time frame: After the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2).

  4. Level of Glycated Haemoglobin (HbA1c) - mmol/Mol

    Level of HbA1c after two weeks of maintenance periods (Visit 19-21 (week 16-17) and Visit 37-39 (week 34-35)).

    Time frame: After the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2).

  5. Mean Glucose Levels Using Flash Glucose Monitoring (FGM)

    Mean glucose levels (mmol/L) during the 2-week maintenance periods using FGM (visit 19-21 (week 16-17) and visit 37-39 (week 34-35)).

    Time frame: During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2).

07

Results

Posted Jan 12, 2021

Participant flow

The trial was conducted in 5 countries as follows: Canada: 10 sites, Poland: 5 sites, Slovakia: 10 sites, South Africa: 7 sites, United States of America: 34 sites

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneSequence A: Insulin Degludec 100U/mL Then Insulin Glargine 100U/mLSequence B: Insulin Glargine 100U/mL Then Insulin Degludec 100U/mL
Started249249
Full analysis set (fas)249249
Safety analysis set (sas)249249
Per protocol set219229
Completed235241
Not completed148
Withdrew: Death01
Withdrew: Lost to follow-up22
Withdrew: Physician decision52
Withdrew: Withdrawal by subject73
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneSequence A: Insulin Degludec 100U/mL Then Insulin Glargine 100U/mLSequence B: Insulin Glargine 100U/mL Then Insulin Degludec 100U/mL
Started235241
Completed230238
Not completed53
Withdrew: Physician decision41
Withdrew: Withdrawal by subject12

Outcome measures

PrimaryPercentage of Time Spent in Glycaemic Target Range 70-180 mg/dL (3.9-10.0 mmol/L) Both Inclusive, Using Flash Glucose Monitoring (FGM)

The percentage of time spent in glycaemic target range was calculated as the number of recorded measurements in glycaemic target range (70-180 milligrams per deciliter \[mg/dL\] (3.9-10.0 millimoles per litre \[mmol/L\]), both inclusive) divided by the total number of recorded measurements. The endpoint is based on data recorded by FGM system. It was required that at least 70% of the planned FGM measurements during weeks 16-17 and weeks 34-35 were available for endpoint data to be included in the analysis.

Time frame:
During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2)
Reported as:
Least squares mean · Percentage of Time
Percentage of Time Spent in Glycaemic Target Range 70-180 mg/dL (3.9-10.0 mmol/L) Both Inclusive, Using Flash Glucose Monitoring (FGM)
Percentage of TimeInsulin Degludec 100U/mLInsulin Glargine 100U/mL
Percentage of Time Spent in Glycaemic Target Range 70-180 mg/dL (3.9-10.0 mmol/L) Both Inclusive, Using Flash Glucose Monitoring (FGM)72.11 ± 0.7470.68 ± 0.74
Statistical analysis
  • Insulin Degludec 100U/mL vs Insulin Glargine 100U/mL · t-test, 2 sided · p = 0.0321 · Estimated treatment difference: 1.43 · 95% CI 0.12 to 2.74
  • Insulin Degludec 100U/mL vs Insulin Glargine 100U/mL · Estimated treatment difference: 1.43 · 95% CI 0.12 to 2.74
SecondaryTime Spent in Tight Glycaemic Target Range 70-140 mg/dL (3.9-7.8 mmol/L) Both Inclusive, Using Flash Glucose Monitoring

The percentage of time spent in tight glycaemic target range 70-140 mg/dL (3.9-7.8 mmol/L) both inclusive, during the 2-week maintenance periods using FGM (visit 9-21 (week 16-17) and visit 37-39 (week 34-35)).

Time frame:
During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2).
Reported as:
Least squares mean · Percentage of Time
Time Spent in Tight Glycaemic Target Range 70-140 mg/dL (3.9-7.8 mmol/L) Both Inclusive, Using Flash Glucose Monitoring
Percentage of TimeInsulin Degludec 100U/mLInsulin Glargine 100U/mL
Time Spent in Tight Glycaemic Target Range 70-140 mg/dL (3.9-7.8 mmol/L) Both Inclusive, Using Flash Glucose Monitoring52.97 ± 0.8251.45 ± 0.82
SecondaryTime Spent in Nocturnal Glycaemic Target Range 70-140 mg/dL (3.9-7.8 mmol/L) Both Inclusive, in the Nocturnal Period (00:01 am - 05:59 am Both Inclusive) Using Flash Glucose Monitoring

Percentage of time spent in nocturnal glycaemic target range 70-140 mg/dL (3.9-7.8 mmol/L) both inclusive, in the nocturnal period (00:01 am - 05:59 am both inclusive) during the 2-week maintenance periods using FGM (visit 19-21 (week 16-17) and visit 37-39 (week 34-35)).

Time frame:
During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2).
Reported as:
Least squares mean · Percentage of Time
Time Spent in Nocturnal Glycaemic Target Range 70-140 mg/dL (3.9-7.8 mmol/L) Both Inclusive, in the Nocturnal Period (00:01 am - 05:59 am Both Inclusive) Using Flash Glucose Monitoring
Percentage of TimeInsulin Degludec 100U/mLInsulin Glargine 100U/mL
Time Spent in Nocturnal Glycaemic Target Range 70-140 mg/dL (3.9-7.8 mmol/L) Both Inclusive, in the Nocturnal Period (00:01 am - 05:59 am Both Inclusive) Using Flash Glucose Monitoring15.15 ± 0.2614.91 ± 0.26
SecondaryLevel of Glycated Haemoglobin (HbA1c) - Percentage

Level of HbA1c after two weeks of maintenance periods (Visit 19-21 (week 16-17) and Visit 37-39 (week 34-35)).

Time frame:
After the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2).
Reported as:
Least squares mean · Percentage of glycated haemoglobin
Level of Glycated Haemoglobin (HbA1c) - Percentage
Percentage of glycated haemoglobinInsulin Degludec 100U/mLInsulin Glargine 100U/mL
Level of Glycated Haemoglobin (HbA1c) - Percentage7.10 ± 0.047.16 ± 0.04
SecondaryLevel of Glycated Haemoglobin (HbA1c) - mmol/Mol

Level of HbA1c after two weeks of maintenance periods (Visit 19-21 (week 16-17) and Visit 37-39 (week 34-35)).

Time frame:
After the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2).
Reported as:
Least squares mean · millimoles per mole (mmol/mol)
Level of Glycated Haemoglobin (HbA1c) - mmol/Mol
millimoles per mole (mmol/mol)Insulin Degludec 100U/mLInsulin Glargine 100U/mL
Level of Glycated Haemoglobin (HbA1c) - mmol/Mol54.10 ± 0.4254.78 ± 0.42
SecondaryMean Glucose Levels Using Flash Glucose Monitoring (FGM)

Mean glucose levels (mmol/L) during the 2-week maintenance periods using FGM (visit 19-21 (week 16-17) and visit 37-39 (week 34-35)).

Time frame:
During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2).
Reported as:
Least squares mean · mmol/L
Mean Glucose Levels Using Flash Glucose Monitoring (FGM)
mmol/LInsulin Degludec 100U/mLInsulin Glargine 100U/mL
Mean Glucose Levels Using Flash Glucose Monitoring (FGM)7.57 ± 0.087.61 ± 0.08

Adverse events

Collected over From the randomization (week 0) up to end of treatment (week 36) and follow up (week 37).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Degludec 100U/mL0/490 (0%)26/490 (5.3%)0/490 (0%)
Insulin Glargine 100U/mL1/484 (0.2%)23/484 (4.8%)0/484 (0%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventInsulin Degludec 100U/mLInsulin Glargine 100U/mL
PneumoniaInfections and infestations3/4902/484
Acute kidney injuryRenal and urinary disorders2/4900/484
Acute coronary syndromeCardiac disorders0/4901/484
Arteriovenous malformationCongenital, familial and genetic disorders0/4901/484
Atrial fibrillationCardiac disorders1/4901/484
Breast massReproductive system and breast disorders0/4901/484
BronchitisInfections and infestations0/4901/484
Cardiac failureCardiac disorders1/4901/484
ContusionInjury, poisoning and procedural complications0/4901/484
Coronary arterial stent insertionSurgical and medical procedures0/4901/484

Baseline characteristics

Full analysis set (FAS) included all randomised participants.

Age, Continuous
Age, Continuous(Years)Overall Study
Mean62.8 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female259
Male239
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino100
Not Hispanic or Latino398
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Overall Study
American Indian or Alaska Native2
Asian23
Black or African American39
White415
Other19
08

Study locations

67 sites
  • Novo Nordisk Investigational Site
    Chandler, Arizona 85224, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85741, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    Lancaster, California 93534, United States
  • Novo Nordisk Investigational Site
    Northridge, California 91325, United States
  • Novo Nordisk Investigational Site
    Poway, California 92064, United States
  • Novo Nordisk Investigational Site
    Van Nuys, California 91405, United States
  • Novo Nordisk Investigational Site
    Hamden, Connecticut 06517, United States
  • Novo Nordisk Investigational Site
    Bradenton, Florida 34201, United States
  • Novo Nordisk Investigational Site
    Cooper City, Florida 33024, United States
  • Novo Nordisk Investigational Site
    Hollywood, Florida 33024, United States
  • Novo Nordisk Investigational Site
    New Port Richey, Florida 34652, United States
  • Novo Nordisk Investigational Site
    Orlando, Florida 32825, United States
  • Novo Nordisk Investigational Site
    Pembroke Pines, Florida 33027, United States
  • Novo Nordisk Investigational Site
    Skokie, Illinois 60077, United States
  • Novo Nordisk Investigational Site
    Topeka, Kansas 66606, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Louisville, Kentucky 40213, United States
  • Novo Nordisk Investigational Site
    Boston, Massachusetts 02115-5804, United States
  • Novo Nordisk Investigational Site
    Boston, Massachusetts 02118, United States
  • Novo Nordisk Investigational Site
    Kalispell, Montana 59901, United States
  • Novo Nordisk Investigational Site
    New Windsor, New York 12553, United States
  • Novo Nordisk Investigational Site
    Greenville, North Carolina 27834, United States
  • Novo Nordisk Investigational Site
    Statesville, North Carolina 28625, United States
  • Novo Nordisk Investigational Site
    Cincinnati, Ohio 45245, United States
  • Novo Nordisk Investigational Site
    Toledo, Ohio 43614, United States
  • Novo Nordisk Investigational Site
    Pelzer, South Carolina 29669, United States
  • Novo Nordisk Investigational Site
    Dakota Dunes, South Dakota 57049, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37203, United States
  • Novo Nordisk Investigational Site
    Amarillo, Texas 79106, United States
  • Novo Nordisk Investigational Site
    Kerrville, Texas 78028, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78215, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78224, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78228-6205, United States
  • Novo Nordisk Investigational Site
    Calgary, Alberta T2H 2G4, Canada
  • Novo Nordisk Investigational Site
    Victoria, British Columbia V8V 4A1, Canada
  • Novo Nordisk Investigational Site
    Concord, Ontario L4K 4M2, Canada
  • Novo Nordisk Investigational Site
    Etobicoke, Ontario M9R 4E1, Canada
  • Novo Nordisk Investigational Site
    London, Ontario N5W 6A2, Canada
  • Novo Nordisk Investigational Site
    Markham, Ontario L3P 7P2, Canada
  • Novo Nordisk Investigational Site
    Oakville, Ontario L6M 1M1, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M4G 3E8, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M6G 1M2, Canada
  • Novo Nordisk Investigational Site
    Montreal, Quebec H4A 2C6, Canada
  • Novo Nordisk Investigational Site
    Bialystok, 15-351, Poland
  • Novo Nordisk Investigational Site
    Bialystok, 15-404, Poland
  • Novo Nordisk Investigational Site
    Gdansk, 80-858, Poland
  • Novo Nordisk Investigational Site
    Lublin, 20-538, Poland
  • Novo Nordisk Investigational Site
    Warsaw, 00-465, Poland
  • Novo Nordisk Investigational Site
    Ponce, 00716, Puerto Rico
  • Novo Nordisk Investigational Site
    Bratislava, 831 01, Slovakia
  • Novo Nordisk Investigational Site
    Bratislava, 851 01, Slovakia
  • Novo Nordisk Investigational Site
    Bytca, 014 01, Slovakia
  • Novo Nordisk Investigational Site
    Levice, 93401, Slovakia
  • Novo Nordisk Investigational Site
    Malacky, 901 01, Slovakia
  • Novo Nordisk Investigational Site
    Nove Mesto nad Vahom, 915 01, Slovakia
  • Novo Nordisk Investigational Site
    Nove Zamky, 940 59, Slovakia
  • Novo Nordisk Investigational Site
    Trebisov, 07501, Slovakia
  • Novo Nordisk Investigational Site
    Trnava, 91701, Slovakia
  • Novo Nordisk Investigational Site
    Zilina, 010 01, Slovakia
  • Novo Nordisk Investigational Site
    Port Elizabeth, Eastern Cape 6045, South Africa
  • Novo Nordisk Investigational Site
    Bloemfontein, Free State 9301, South Africa
  • Novo Nordisk Investigational Site
    Johannesburg, Gauteng 1827, South Africa
  • Novo Nordisk Investigational Site
    Johannesburg, Gauteng 1829, South Africa
  • Novo Nordisk Investigational Site
    Lenasia, Gauteng 1827, South Africa
  • Novo Nordisk Investigational Site
    Pretoria, Gauteng 0044, South Africa
  • Novo Nordisk Investigational Site
    Cape Town, Western Cape 7130, South Africa
09

References and documents

Publications

  • Goldenberg RM, Aroda VR, Billings LK, Christiansen ASL, Meller Donatsky A, Parvaresh Rizi E, Podgorski G, Raslova K, Klonoff DC, Bergenstal RM. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. Diabetes Obes Metab. 2021 Nov;23(11):2572-2581. doi: 10.1111/dom.14504. Epub 2021 Aug 16. PubMed 34322967 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Dec 2019, 14 months.

Results were first posted in Jan 2021, 1 year after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 14 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2018
First posted
Sep 27, 2018
StartActual
Oct 2, 2018
Primary completionActual
Dec 20, 2019
CompletionActual
Dec 27, 2019
Results first posted
Jan 12, 2021
Last update
Jan 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03687827
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 27, 2018
Start date
Oct 2, 2018
Primary completion
Dec 20, 2019
Completion
Dec 27, 2019
Results posted
Jan 12, 2021
Last update
Jan 12, 2021

Study contacts

Clinical Reporting Anchor and Disclosure (1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin degludec

Start the discussion